| Literature DB >> 35051135 |
Katrin S Sadigh, Irfan Elahi Akbar, Mufti Zubair Wadood, Hemant Shukla, Jaume Jorba, Sumangala Chaudhury, Maureen Martinez.
Abstract
Wild poliovirus types 2 and 3 were declared eradicated in 2015 and 2019, respectively, and, since 2017, transmission of wild poliovirus type 1 (WPV1) has been detected only in Afghanistan and Pakistan. In 2020, these countries reported their highest number of WPV1 cases since 2014 and experienced outbreaks of type 2 circulating vaccine-derived poliovirus (cVDPV2)* (1); in Afghanistan, the number of WPV1 cases reported increased 93%, from 29 in 2019 to 56 in 2020, with 308 cVDPV2 cases reported. This report describes the activities and progress toward polio eradication in Afghanistan during January 2020-November 2021 and updates previous reports (2-4). Despite restrictions imposed by antigovernment elements since 2018, disruption of polio eradication efforts by the COVID-19 pandemic, and civil and political instability, eradication activities have resumed. During January-November 2021, four WPV1 cases and 43 cVDPV2 cases were detected, representing decreases of 93% from 56 and 85% from 281, respectively, during the same period in 2020. After the assumption of nationwide control by the current de facto government of Afghanistan during August 2021, health officials committed to oral poliovirus vaccine (OPV) campaigns nationwide, with the potential to vaccinate approximately 2.5 million children against poliovirus who were previously not accessible for ≥2 years. Although challenges remain, vigorous, sustained polio eradication efforts in Afghanistan could result in substantial progress toward eradication during 2022-2023.Entities:
Mesh:
Substances:
Year: 2022 PMID: 35051135 PMCID: PMC8774155 DOI: 10.15585/mmwr.mm7103a3
Source DB: PubMed Journal: MMWR Morb Mortal Wkly Rep ISSN: 0149-2195 Impact factor: 17.586
Acute flaccid paralysis surveillance performance indicators, reported cases of wild poliovirus and vaccine-derived poliovirus type 2,* and percentage of environmental samples with detection of wild poliovirus type 1, by region and period ― Afghanistan, January 2020–November 2021
| Region | AFP surveillance indicators | No. of WPV1 cases reported | No. of cVDPV2 cases reported | No. (%) of ES samples with WPV1 detected§ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No. of AFP cases | NPAFP rate (%)¶ | % with adequate stool specimens** | 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | |||||||
| 2020 | 2021 | 2020 | 2021 | 2020 | 2021 | Jan–Jun | Jul–Dec | Jan–Nov | Jan–Jun | Jul–Dec | Jan–Nov | Jan–Jun | Jul–Dec | Jan–Nov | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Badakhshan | 83 | 61 | 12 | 10 | 89 | 93 | 1 | 0 | 0 | 1 | 0 | 0 | 0 (―) | 0(―) | 0 (―) |
| Central | 734 | 658 | 15 | 17 | 98 | 98 | 0 | 0 | 0 | 0 | 17 | 4 | 0 (―) | 1 (3) | 0 (―) |
| Eastern | 543 | 374 | 24 | 20 | 92 | 96 | 2 | 0 | 0 | 51 | 19 | 0 | 2 (2) | 2 (3) | 0 (―) |
| Northeastern | 429 | 298 | 18 | 15 | 95 | 94 | 0 | 0 | 3 | 0 | 4 | 0 | 0 (―) | 1 (20) | 0 (―) |
| Northern | 337 | 255 | 13 | 12 | 91 | 89 | 1 | 0 | 0 | 0 | 7 | 2 | 0 (―) | 0 (―) | 0 (―) |
| Southeastern | 426 | 283 | 20 | 15 | 95 | 96 | 0 | 6 | 1 | 1 | 33 | 8 | 1 (8) | 0 (―) | 0 (―) |
| Southern | 798 | 586 | 21 | 18 | 86 | 89 | 23 | 15 | 0 | 0 | 145 | 12 | 17 (26) | 7 (9) | 1 (0.8) |
| Western | 622 | 494 | 20 | 20 | 93 | 93 | 7 | 1 | 0 | 1 | 29 | 17 | 2 (29) | 2 (40) | 0 (―) |
Abbreviations: AFP = acute flaccid paralysis; cVDPV2 = circulating vaccine-derived poliovirus type 2; ES = environmental surveillance; NPAFP = nonpolio acute flaccid paralysis; WPV1 = wild poliovirus type 1.
* cVDPVs are genetically linked VDPV2 isolates for which there is evidence of person-to-person transmission within the community.
† Data as of January 11, 2022.
§ Total number of ES samples by period: January 2020–June 2020 = 208, July 2020–December 2020 = 205, and January 2021–November 2021 = 341. WPV-1–positive ES samples were detected in 2020 in Kabul (central), Nangarhar (eastern), Kunduz (northeastern), Khost (southeastern), and Helmand and Kandahar (southern) provinces, and in 2021 in Helmand (southern) province. Percentages indicate specimens testing positive for WPV1 for the total number of specimens collected for all regions and the specific region during that period.
¶ Cases per 100,000 persons aged <15 years. The surveillance performance indicator target is ≥2 NPAFP cases per 100,000 persons aged <15 years.
** Surveillance performance indicator target is ≥80% of AFP cases have adequate stool specimens collected. Adequate stool specimens are defined as two stool specimens of sufficient quality for laboratory analysis, collected ≥24 hours apart, both within 14 days of paralysis onset, and arriving in good condition at a World Health Organization-accredited laboratory with reverse cold chain maintained, without leakage or desiccation, and with proper documentation.
Figure 1Cases of wild poliovirus type 1 and circulating vaccine-derived poliovirus type 2,*,† by province and period — Afghanistan, January 2020–November 2021
Abbreviations: cVDPV2 = circulating vaccine-derived poliovirus type 2; WPV1 = wild poliovirus type 1.
* cVDPVs are genetically linked VDPV2 isolates for which there is evidence of person-to-person transmission in the community.
† Total cases by period: January–June 2020 = 34 WPV1 and 54 cVDPV2; July–December 2020 = 22 WPV1 and 254 cVDPV2; and January–November 2021 = 4 WPV1 and 43 cVDPV2.
§ Data as of January 11, 2022.
Figure 2Number of wild poliovirus type 1 cases (n = 60) and circulating vaccine-derived poliovirus type 2* cases, by month of onset of paralysis (n = 351) — Afghanistan, January 2020–November 2021
Abbreviations: cVDPV2 = circulating vaccine-derived poliovirus type 2; WPV1 = wild poliovirus type 1.
* cVDPVs are genetically linked VDPV2 isolates for which there is evidence of person-to-person transmission in the community.
† Data as of January 11, 2022.